Stock FCM FRIULCHEM S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Friulchem S.p.A.

Equities

FCM

IT0005378457

Market Closed - Borsa Italiana
Other stock markets
 16:44:59 30/04/2024 BST 		5-day change 1st Jan Change
0.985 EUR -.--% Intraday chart for Friulchem S.p.A. +0.51% -1.50%
03-22 Friulchem returns to profit in 2023; increases financial debt AN
03-22 Friulchem S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.52 for the 2023 fiscal year.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
FRIULCHEM S.P.A. Stock Friulchem S.p.A.
-1.50% 6.31M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 699B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.59% 571B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 364B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 326B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.36% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.81% 236B
B+
NOVARTIS AG Stock Novartis AG
+4.93% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
A+
AMGEN INC. Stock Amgen Inc.
-3.69% 149B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. FCM Stock
  4. Ratings Friulchem S.p.A.